大葉大學圖書館 |

Novel biomarkers in the continuum of breast cancer[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.99449075
書名/作者:	Novel biomarkers in the continuum of breast cancer/ edited by Vered Stearns.
其他作者:	Stearns, Vered.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	xix, 279 p. : : ill. (some col.), digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Tumor markers.
標題:	Breast - Cancer
標題:	Breast - Cancer
標題:	Biomedicine.
標題:	Cancer Research.
標題:	Oncology.
標題:	Human Genetics.
ISBN:	9783319229096
ISBN:	9783319229089
內容註:	1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.
摘要、提要註:	This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today's standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.
電子資源:	http://dx.doi.org/10.1007/978-3-319-22909-6

Novel biomarkers in the continuum of breast cancer[electronic resource] /
Novel biomarkers in the continuum of breast cancer[electronic resource] /edited by Vered Stearns. - Cham :Springer International Publishing :2016. - xix, 279 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.8820065-2598 ;. - Advances in experimental medicine and biology ;946..

1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.

This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today's standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.

ISBN: 9783319229096

Standard No.: 10.1007/978-3-319-22909-6doiSubjects--Topical Terms:

470235
Tumor markers.

LC Class. No.: RC270.3.T84

Dewey Class. No.: 616.99449075

Novel biomarkers in the continuum of breast cancer[electronic resource] /
LDR:02649nam a2200325 a 4500 001 446425
003 DE-He213
005 20160908155904.0
006 m d
007 cr nn 008maaau
008 161201s2016 gw s 0 eng d
020 $a 9783319229096 $q (electronic bk.)
020 $a 9783319229089 $q (paper)
024 7 $a 10.1007/978-3-319-22909-6 $2 doi
035 $a 978-3-319-22909-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.3.T84
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99449075 $2 23
090 $a RC270.3.T84 $b N937 2016
245 0 0 $a Novel biomarkers in the continuum of breast cancer $h [electronic resource] / $c edited by Vered Stearns.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a xix, 279 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.882
505 0 $a 1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.
520 $a This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today's standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.
650 0 $a Tumor markers. $3 470235
650 0 $a Breast $x Cancer $x Diagnosis. $3 387697
650 0 $a Breast $x Cancer $x Molecular aspects. $3 634257
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Oncology. $3 205017
650 2 4 $a Human Genetics. $3 464334
700 1 $a Stearns, Vered. $3 639061
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 463635
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-22909-6
950 $a Biomedical and Life Sciences (Springer-11642)